Table 2 chRCC patient´s and tumor characteristics in dependence of HGF expression
From: Immunohistochemical expression of the hepatocyte growth factor in chromophobe renal cell carcinoma
Variable | All chRCC n = 81 (100%) | HGF- n = 44 (54.3%) | HGF+ n = 37 (45.6%) | p-value |
|---|---|---|---|---|
Age, median (IQR) years | 59.8 (52.9–69.1) | 62.7 (51.2–71.1) | 59.4 (53.2–67.6) | 0.649a |
Sex | 0.472b | |||
female | 23 (28.4%) | 11 (25.0%) | 12 (32.4%) | |
male | 58 (71.6%) | 33 (75.0%) | 25 (67.6%) | |
Stage (TNM 2010) | 0.639c | |||
pT1 | 60 (74.1) | 34 (77.3%) | 26 (70.3%) | |
pT2 | 14 (17.3) | 6 (13.6%) | 8 (21.6%) | |
pT3 | 7 (8.6) | 4 (9.1%) | 3 (8.1%) | |
Cancer Stage (AJCC) | 0.612c | |||
Stage I | 56 (69.1) | 33 (75.0%) | 23 (62.2%) | |
Stage II | 14 (17.3) | 6 (13.6%) | 8 (21.6%) | |
Stage III | 8 (9.9) | 4 (9.1%) | 4 (10.8%) | |
Stage IV | 3 (3.7) | 1 (2.3%) | 2 (5.4%) | |
LN metastasis # | 0.590b | |||
N- | 78 (96.3) | 43 (97.7%) | 35 (94.6%) | |
N+ | 3 (3.7) | 1 (2.3%) | 2 (5.4%) | |
Metastasis# | 0.590b | |||
M- | 78 (96.3) | 43 (97.7%) | 35 (94.6%) | |
M+ | 3 (3.7) | 1 (2.3%) | 2 (5.4%) | |
Disease status | 0.537b | |||
Localized * | 70 (86.4) | 39 (88.6%) | 31 (83.8%) | |
Advanced $ | 11 (13.6) | 5 (11.4%) | 6 (16.2%) |